Edition:
United Kingdom

Forward Pharma A/S (FWP.OQ)

FWP.OQ on NASDAQ Stock Exchange Global Select Market

2.60USD
24 Sep 2018
Change (% chg)

$0.22 (+9.24%)
Prev Close
$2.38
Open
$2.38
Day's High
$2.60
Day's Low
$2.31
Volume
1,337
Avg. Vol
10,970
52-wk High
$7.84
52-wk Low
$1.64

Latest Key Developments (Source: Significant Developments)

Mark Lampert Reports 11.3 Percent Passive Stake In Forward Pharma A/S
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Forward Pharma A/S ::MARK LAMPERT REPORTS 11.3 PERCENT PASSIVE STAKE IN FORWARD PHARMA A/S AS OF DECEMBER 22 .  Full Article

Forward Pharma Files Further Written Submissions In European Opposition Proceeding For EP2801355 Patent
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Forward Pharma A/S ::FORWARD PHARMA FILES FURTHER WRITTEN SUBMISSIONS IN THE EUROPEAN OPPOSITION PROCEEDING FOR THE EP2801355 PATENT IN PREPARATION FOR THE ORAL HEARING IN JANUARY 2018.FORWARD PHARMA A/S - FILING OF FURTHER WRITTEN SUBMISSIONS IN EUROPEAN OPPOSITION PROCEEDING FOR EP2801355 PATENT WITH EPO.FORWARD PHARMA A/S - FILING WILL BECOME PUBLICLY AVAILABLE VIA EUROPEAN PATENT REGISTER.FORWARD PHARMA A/S - AN ORAL HEARING IS CURRENTLY SCHEDULED FOR JANUARY 29-30, 2018.FORWARD PHARMA A/S - POSSIBILITY TO APPEAL DECISION OF OPPOSITION DIVISION TO TECHNICAL BOARD OF APPEAL.  Full Article

Forward Pharma announces completion of corporate restructuring plan
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Forward Pharma A/S :Forward Pharma announces completion of corporate restructuring plan.  Full Article

Forward Pharma receives $1.25 bln pursuant to settlement and license agreement with Biogen
Thursday, 9 Feb 2017 

Forward Pharma A/S - : Forward Pharma received US$ 1.25 bln pursuant to settlement and license agreement with Biogen .Forward Pharma A/S - received non-refundable cash fee of US$1.25 billion in connection with settlement and license agreement with two units of Biogen.  Full Article

BRIEF-Forward Pharma Appeals The Decision Of The Opposition Division To Revoke The EP2801355 Patent

* FORWARD PHARMA APPEALS THE DECISION OF THE OPPOSITION DIVISION TO REVOKE THE EP2801355 PATENT